Autolus Therapeutics PLC
NASDAQ:AUTL

Watchlist Manager
Autolus Therapeutics PLC Logo
Autolus Therapeutics PLC
NASDAQ:AUTL
Watchlist
Price: 2.68 USD 2.68% Market Closed
Market Cap: 713.3m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

AUTL Price Targets Summary
Autolus Therapeutics PLC

Wall Street analysts forecast AUTL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AUTL is 9.86 USD with a low forecast of 5.76 USD and a high forecast of 13.65 USD.

AUTL Lowest Forecast
Wall Street Target
5.76 USD
115% Upside
AUTL Average Forecast
Wall Street Target
9.86 USD
268% Upside
AUTL Highest Forecast
Wall Street Target
13.65 USD
409% Upside
Lowest
Price Target
5.76 USD
115% Upside
Average
Price Target
9.86 USD
268% Upside
Highest
Price Target
13.65 USD
409% Upside
Autolus Therapeutics PLC Competitors:
Price Targets
P
214450
PharmaResearch Co Ltd
8% Downside
ACAD
ACADIA Pharmaceuticals Inc
24% Upside
SKYE
Skye Bioscience Inc
302% Upside
CSL
CSL Ltd
17% Upside
P
214450
PharmaResearch Co Ltd
8% Downside
ACAD
ACADIA Pharmaceuticals Inc
24% Upside
SKYE
Skye Bioscience Inc
302% Upside
CSL
CSL Ltd
17% Upside
300601
Shenzhen Kangtai Biological Products Co Ltd
6% Upside
4593
Healios KK
18% Downside
NBIX
Neurocrine Biosciences Inc
22% Upside
S
6955
Shandong Boan Biotechnology Co Ltd
39% Downside

Revenue
Forecast

Revenue Estimate
Autolus Therapeutics PLC

For the last 7 years the compound annual growth rate for Autolus Therapeutics PLC's revenue is 29%. The projected CAGR for the next 3 years is 197%.

29%
Past Growth
197%
Estimated Growth
Estimates Accuracy
-14%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Autolus Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Autolus Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-68%
Average Miss
What are analyst estimates?

See Also

Summary
AUTL intrinsic value, competitors valuation, and company profile.
DCF Valuation
AUTL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AUTL stock valuation using valuation multiples.
Wall Street Estimates
AUTL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AUTL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is AUTL's stock price target?
Price Target
9.86 USD

According to Wall Street analysts, the average 1-year price target for AUTL is 9.86 USD with a low forecast of 5.76 USD and a high forecast of 13.65 USD.

What is Autolus Therapeutics PLC's Revenue forecast?
Projected CAGR
197%

For the last 7 years the compound annual growth rate for Autolus Therapeutics PLC's revenue is 29%. The projected CAGR for the next 3 years is 197%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 270,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.